Full detail content for this treatment is being translated. For a localized consultation in English, please contact our coordinators — we respond within 24 hours.
Six-Cell Combination Immunotherapy
Six-Cell Combination Immunotherapy
Simultaneously activates six key immune-cell types with 2–5 billion active fighters per infusion. Developed by Dr. Tsuneo Kuramochi (deceased), it offers patients with metastatic or recurrent cancer a new route to rebuild their immune defenses.
What Is the Kuramochi Six-Cell Combination Immunotherapy?
Conventional immune-cell therapies typically focus on a single cell type (such as NK or DC), but cancer is a cunning adversary — a single "unit" cannot encircle it on every front.
The Kuramochi Six-Cell Combination Immunotherapy is built on "combined-arms" warfare — extracting and activating six different immune-cell types from the patient's blood in parallel.
"By raising the cell count from tens of millions to 2–5 billion and combining specific and non-specific attacks from multiple cell types, the killing efficiency against cancer cells is dramatically enhanced."
γδT Cells
Innate Immunity · Direct Attack
NK Cells
Natural Killers · Immediate Response
NKT Cells
Immune Bridge · Powerful Booster
Cytotoxic T Cells (CTL)
Specific Attack · Main Force
Dendritic Cells (DC)
Antigen Presentation · Intelligence Hub
Helper T Cells (Th)
Immune Commander · Coordinator
Six-Cell Immune Network Diagram
γδT → NK → NKT → CTL → DC → Th form a complete multi-arm immune attack network
Schematic of six immune cells cooperatively attacking cancer cells (Senshin Clinic)
GMP-compliant cell-processing center (CPC)
The Six Immune Cells Explained
Sea, land and air forces working together — a defensive and offensive network with no blind spots
γδT Cells
Innate Immunity · Direct Attack
Part of the innate immune system; recognizes and attacks many cancer-cell types directly, without HLA restriction.
NK Cells
Natural Killers · Immediate Response
Natural killer cells that precisely destroy stealthy cancer cells with loss of MHC class I — no antigen presentation required.
NKT Cells
Immune Bridge · Powerful Booster
Combining T-cell and NK-cell traits, they secrete abundant cytokines to activate the entire immune network.
Cytotoxic T Cells (CTL)
Specific Attack · Main Force
After receiving orders from dendritic cells, they deliver precise, destructive strikes against specific cancer antigens such as WT1.
Dendritic Cells (DC)
Antigen Presentation · Intelligence Hub
Capture cancer antigens and relay this intelligence to T cells, triggering the specific immune response.
Helper T Cells (Th)
Immune Commander · Coordinator
Secrete cytokines that direct the immune response, keeping the system operating efficiently and with staying power.
Treatment Features
Japan-Korea Dual Patents
Developed by Dr. Kuramochi; officially patented in Japan and Korea, with a proprietary culture protocol.
2–5 Billion Cells per Infusion
A single drip delivers 2–5 billion active immune cells, far more than traditional single-cell therapies.
Applicable to Most Cancer Types
Suitable for solid cancers (lung, gastric, breast, etc.) and metastatic or recurrent cases.
Very Low Side Effects
Cultured from the patient's own blood — no rejection; most patients experience only brief, mild fever.
No Hospitalization · Outpatient
Only a blood draw and an infusion are needed; each session requires only brief on-site observation and does not disrupt daily life.
Synergistic with Standard Care
Can be combined with chemotherapy and radiotherapy to help reduce side effects and improve overall response rates.
Four common concerns — and honest answers
Specific answers depend on your medical record and your attending physician. We ensure language is not a barrier to your understanding.
Q1Will it hurt?
Pain depends on the person and the procedure. Japanese hospitals follow a complete pain-management workflow: pre-procedure assessment, intra-procedural anaesthesia, and post-procedural pain control. You can ask your attending physician about expected pain at the pre-procedure briefing — our interpreter will translate question and answer accurately.
Q2How serious are the side effects?
Side effects differ by therapy. Before you sign consent, Japanese hospitals will walk you through the possible side effects, their probability, and how they are managed. If anything is unclear, we will ask the physician to re-explain until you fully understand before signing.
Q3How long is the hospital stay?
It depends on the therapy. Day treatments require no admission; some therapies need 1–3 days of observation; surgery or particle therapy may need 1–3 weeks. Your physician will note the duration in the treatment plan, and we translate the plan for you and your family.
Q4How soon after treatment can I fly home?
Day treatments and outpatient therapies usually allow same-day or next-day flights. For therapies with hospitalisation, you typically observe for 2–3 days post-discharge, and your physician issues a fitness-to-fly note. We help you book a flexible return ticket.
This section is general guidance. Specific expectations, suitability, and timing must be determined by your attending physician in Japan based on your complete medical record.
Medical information disclaimer
The information on this page is for educational reference only and does not constitute medical advice. The suitability, side effects, and expected outcomes of any therapy must be determined by your attending physician in Japan based on your complete medical record. Medical Supporter does not replace any professional medical judgement.
Treatment Process
Precise cultivation, safeguarding life
Initial 30 ml Blood Draw
About 30 ml of blood is drawn from the patient's arm as the source of primary immune cells, together with a full health assessment.
Separation & Antigen Presentation
Lymphocytes are isolated in the CPC lab and primed with WT1 or cancer stem-cell (CSC) antigens for tagging and presentation.
Three-Week Precision Culture
Patented technology grows all six cell types in parallel to 2–5 billion, keeping their activity and attack potential at peak levels.
Intravenous Reinfusion
All six cultured cell types are reinfused intravenously, launching system-wide immune surveillance and attack.
One Treatment Cycle
A full treatment cycle typically lasts 3–5 months with 6 infusions, spaced 2–4 weeks apart.
- Month 1: blood draw and the first 2 infusions
- Month 2: the next 2 infusions
- Month 3: the final 2 infusions and response evaluation
Who It's For
Applicable to almost all solid cancers, with the exception of certain leukemias (e.g., T-cell leukemia) and some malignant lymphomas.
Founder: Dr. Tsuneo Kuramochi (deceased)
Dr. Tsuneo Kuramochi (deceased), M.D., Ph.D.
Academic CV
- • Developer of the "Kuramochi-style Six-Cell Combination Immunotherapy"
- • Holder of patents in both Japan and Korea
- • Technology development at Fukuoka Dojin Clinic
Current Medical Team
Director Dr. Toshihide Aso
Current director of Fukuoka Dojin Clinic; leads daily outpatient care and clinical protocols, continuing Dr. Kuramochi's spirit of immune-therapy research and delivering precision medicine to patients.
Recommended Medical Institutions
We connect you with specialized Japanese clinics with deep experience.
Fukuoka Dojin Clinic
Fukuoka Dojin Clinic
The birthplace of the Kuramochi six-cell combination immunotherapy; holds dual Japan-Korea patents and focuses on high-quality cell culture.
View DetailsFukuoka Cancer General Clinic
Fukuoka Cancer General Clinic
Hosts an in-house certified CPC lab dedicated to high-quality autologous immune-cell culture and personalized cancer vaccines.
View DetailsReboot Your Immune System
Medical Supporter arranges specialist consultations, medical interpretation, and full trip coordination in Japan.
Let us help you access Japan's patented six-cell combination immunotherapy protocol.